title: CDK4/6 inhibition and sorafenib: a ménage à deux in HCC therapy?
authors.affiliation: Institute of Pathology, University Medicine, University of Greifswald, Greifswald, Germany.
authors.forename: Diego
authors.initials: D
authors.lastname: Calvisi
authors.affiliation: Medical University Vienna & Comprehensive Cancer Center (CCC), Institute of Cancer Research, Vienna, Austria.
authors.forename: Robert
authors.initials: R
authors.lastname: Eferl
mesh_terms: D000970:Antineoplastic Agents; D017209:Apoptosis / Q000187:drug effects; D006528:Carcinoma, Hepatocellular; D045744:Cell Line, Tumor; D006801:Humans; D008113:Liver Neoplasms; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib
keywords: CELL CYCLE; HEPATOCELLULAR CARCINOMA; PHARMACOTHERAPY